CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 263,211	$ 230,276
Marketable securities	182,112	77,819
Accounts receivable - trade, net	855,844	593,207
Accounts receivable from Sanofi	136,980	99,913
Deferred tax assets	39,174	148,134
Prepaid expenses and other current assets	156,839	56,663
Total current assets	1,634,160	1,206,012
Restricted cash and marketable securities		8,186
Marketable securities	329,863	271,230
Property, plant, and equipment, at cost, net of accumulated depreciation and amortization	453,891	379,940
Deferred tax assets	218,092	192,022
Other assets	4,409	23,100
Total assets	2,640,415	2,080,490
Current liabilities:
Accounts payable and accrued expenses	219,138	111,345
Deferred revenue from Sanofi, current portion	13,866	17,022
Deferred Revenue - other, current portion	34,929	33,809
Facility lease obligations, current portion	794	1,374
Total current liabilities	268,727	163,550
Deferred revenue from Sanofi	77,670	76,520
Deferred Revenue - other	111,893	131,822
Facility lease obligations	167,219	159,436
Convertible senior notes	314,162	296,518
Other long term liabilities	10,573	7,259
Total liabilities	950,244	835,105
Commitments and contingencies
Stockholders' equity:
Preferred stock
Additional paid-in capital	1,882,421	1,763,508
Accumulated deficit	(189,498)	(517,054)
Accumulated other comprehensive loss	(2,851)	(1,166)
Total stockholders' equity	1,690,171	1,245,385
Total liabilities and stockholders' equity	2,640,415	2,080,490
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 97	$ 95